GlassScriptPhysician profile
Nora Nikprelevic
NPI 1760131692
$1,575.94
in general payments reported to CMS, 2019-2025
14 companies · $974 in 2025
The $974 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $52.08 · 2024: $550 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,575.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $531.62 | 2024-2025 | |
| Ucb, INC. | $282.87 | 2025 | Fintepla, Rystiggo, Nayzilam |
| Neurelis, INC. | $166.89 | 2024-2025 | Valtoco |
| Argenx US, INC. | $124.99 | 2024 | Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $114.40 | 2023-2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $90.52 | 2023-2024 | Hyqvia |
| Merz Pharmaceuticals, LLC | $81.51 | 2024-2025 | Xeomin, Ampyra, Inbrija |
| Emd Serono, INC. | $49.30 | 2025 | Mavenclad |
| Astrazeneca Pharmaceuticals LP | $27.28 | 2025 | |
| Immedica Pharma US, INC. | $24.52 | 2025 | Ztalmy |
| Catalyst Pharmaceuticals, INC. | $23.74 | 2024 | |
| Upsher-Smith Laboratories LLC | $22.42 | 2025 | |
| Acorda Therapeutics, INC | $19.19 | 2024 | Inbrija |
| Neurocrine Biosciences, INC. | $16.69 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Nikprelevic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.